The ADHD-Anxiety Double Act: Why a New Drug Might Change the Conversation

The ADHD-Anxiety Double Act: Why a New Drug Might Change the Conversation

If youve ever tried to treat ADHD while anxiety quietly pulls the strings in the background, you know the frustration. Stimulants can feel like throwing gasoline on a anxious fire. SSRIs, the usual go-to for anxiety, can take weeks to work and sometimes make things worse before they get better. And for a huge chunk of adults with ADHD—especially young adults—this isnt a rare edge case. Its the rule, not the exception.

Thats the backdrop for a new phase 3b trial that has clinicians paying attention. Centanafadine, a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) and central nervous system stimulant, was already approved by the FDA for ADHD. Now, new data presented at Psych Congress 2026 show it might do something its predecessors couldnt: tackle both ADHD and comorbid anxiety at the same time.

What the Numbers Actually Say

The trial enrolled 315 adults with ADHD and either generalized anxiety disorder or social anxiety disorder. On the primary endpoint—the Adult ADHD Investigator Symptom Rating Scale (AISRS)—centanafadine beat placebo by a treatment difference of −5.87 points. Thats not just statistically significant; its clinically meaningful. In plain English, patients didnt just score better on a spreadsheet. They functioned better.

But the headline thats really turning heads is the key secondary endpoint. On the Hamilton Anxiety Rating Scale (HAM-A), the drug produced a treatment difference of −1.92 points. Thats a concurrent anxiolytic signal—a fancy way of saying it calmed anxiety while treating ADHD. For anyone whos watched a patient spiral on a traditional amphetamine-based stimulant, thats a big deal.

“Certain stimulants, for example, the traditional amphetamine-based stimulants, and even certain SSRIs can actually, at least initially worsen anxiety symptoms,” said John Kraus, MD, PhD, executive vice president and chief medical officer at Otsuka Pharmaceutical Companies. “So we were very pleased to see in this population an improvement in both symptoms.”

Beyond the Core Symptoms

ADHD isnt just about focus and hyperactivity. As people age, life gets messier. Relationships, work, bills—the executive function demands ramp up. The trial looked at that too. Centanafadine showed positive effects on executive function (planning, organizing, following through) and emotional control (the ability to regulate mood swings and reactivity).

That matters because these are the symptoms that often derail careers and relationships, not just the inability to sit still in a meeting. “As persons with ADHD age and their lives become more complex, relationships become more complex, certain symptoms also become more important,” Kraus noted. “We saw positive effects on executive function… Additionally, theres something called emotional control.”

The Mechanism Question (And Why Its Okay to Say We Dont Know for Sure)

Centanafadine is a triple reuptake inhibitor. It blocks the reuptake of norepinephrine, dopamine, and serotonin. The first two are familiar territory for ADHD drugs. The serotonin piece is where things get interesting—and speculative.

“The serotonin component may actually contribute to some of the findings were seeing here today in terms of the anxiety, as well as in terms of the other symptoms… including emotional dyscontrol,” Kraus said. “However, I have to stress thats speculative.”

That honesty is refreshing. We know what the drug does at the transporter level. What happens downstream in complex circuits over time is a different story. But based on what we know about each neurotransmitter individually, the combination makes sense.

Why This Matters for Real Patients

Heres the practical takeaway: ADHD with comorbid anxiety isnt a niche. Its a massive subset of patients. And one medication doesnt work for everyone. Having another option—especially one that isnt a traditional amphetamine—gives clinicians and patients more room to maneuver.

“Potentially a broader population may benefit, including those with comorbidities, maybe helping simplify their medical treatments over time,” Kraus said. “It is also important that there are options that arent necessarily traditional stimulants, like amphetamines, because some patients do want to avoid those and some parents want to avoid those as well.”

That last point is worth sitting with. For young adults just starting college or their first job, simplifying a treatment regimen—one drug instead of two or three—can mean the difference between sticking with it and giving up.

The Bottom Line

Centanafadine isnt a miracle cure. No drug is. But for adults with ADHD and anxiety whove struggled to find a regimen that doesnt trade one problem for another, this data offers something genuinely new: a signal that both conditions can be addressed together, without the anxiety spike that so often comes with traditional stimulants.

The next step is yours. If youre a clinician, ask yourself: how many of your ADHD patients are silently struggling with anxiety? If youre a patient, ask your prescriber: is there an option that treats both? The conversation is changing. Make sure youre part of it.

Related Articles

The ADHD and Autism Diagnosis Shift: Why Todays Diagnosed Kids Look More Like Everyone Else

Zombieing: The Dating Trend That Makes Ghosting Look Like a Warm-Up

The ADHD Misdiagnosis Hiding in Your Childs Bedtime Routine

The Brains Blue Place Isnt a Foghorn — Its a Precision Postal Network, Scientists Discover

When Neurodivergent Becomes a Catch-All, Science Gets Lost in Translation

The Word Neurodivergent Is Everywhere. Science Says We Still Dont Know What It Means.